1832 Asset Management L.P. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
1832 Asset Management L.P. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2022$550.0%0.00%
Q3 2022$050.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders